Unlike the current FDA-approved PSMA PET tracers, low levels of kidney uptakes were noted with 89Zr-DFO-MSTP2109A, and 16 of the 17 PET-positive lesions were biopsy proven to be prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.